Shuba N.M. 1, Tarasenko T.N. 2

Summary. Summary. In order to determine a differentiated approach in the treatment of gonarthrosis anti-inflammatory drugs, depending on the bone mineral density (BMD) were evaluated results of a study involving 140 patients (128 females, 12 males) with gonarthrosis II–III radiological stage by Kellgren — Lawrence. All patients gonarthrosis, depending onthe therapy, were divided into 4 equal groups of 35 patients. Group I patients received chondroitin sulfate 4.6 avian origin 500 mg 2 times a day for 6 months and nimesulide in granular form 100 mg 2 times a day to 15 days. Patients in Group II received chondroitin sulfate 4.6 to 1 g per day for 6 months and diclofenac 50 mg 3 times per day to 15 days. Group III patients only took nimesulide 200 mg per day up to 15 days. Group IV patients received 150 mg of diclofenac per day up to 15 days. When expressed pain syndrome underwent a course of NSAID therapy is repeated at intervals of not less than 2 weeks. Six months after the start of the study in ultrasound densitometry was found negative dynamics of T-index and Z-index for 6 months in the standard deviations in groups III and IV patients, but a year later the ne­gative dynamics was observed already in patients of all groups, with significantly fewer patients I and II groups, who are appointed by chondroitin sulfate. After 6 months there was a significant reduction in Z-index patients of Group IV compared to Group III, indicating that the loss of bone mass in patients in group III was significantly less significant. Thus, the positive impact of chondroitin sulfate on BMD. The high clinical efficacy and pronounced aftereffect of chondroitin sulphate in patients with knee OA II–III radiological stage by Kellgren — Lawrence.

No Comments » Add your
Leave a comment